Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Martin Plöderl
From Efficacy to Non-Efficacy: Lessons from Pediatric Fluoxetine Trials
Fluoxetine is recommended as a first-line antidepressant to treat pediatric depression in major guidelines, and it is one of the most widely prescribed antidepressants for children and adolescents. However, modern studies find that fluoxetine has lost its efficacy and can now be considered clinically equivalent to placebo. In this piece, I will explain this puzzling phenomenon, which is also crucial for judging the efficacy of other common antidepressants.
Approving a Drug for Children and Adolescents That Is More Likely to Induce Suicidality Than Relieve Anxiety Is Concerning
In this blog I review the approval of escitalopram for generalized anxiety disorder (GAD) in children and adolescents and critically discuss the FDA approval document and the approval trial. In the approval trial, for the primary outcome, efficacy was not clinically meaningful, statistical significance was uncertain, and there were significantly more adverse events with escitalopram than with placebo.
Reply to “Some additional considerations on the evidence for flouxetine in pediatric depression”
Letter to the EditorArticles in Press112138 aDepartment of Inpatient Psychotherapy and Crisis Intervention, University Clinic for Psychiatry, Psychotherapy, and Psychosomatics, Christian Doppler Clinic, Paracelsus Medical University, Salzburg, Austria bCore CAMHS Team, Brookside Family Consultation Clinic, Trumpington Road, Cambridge, CB2 8AH, UK cResearch and Development Department, North East London NHS Foundation Trust (NELFT), Rainham, UK dInstitute of Pharmaceutical Sciences, King’s...
The loss of efficacy of fluoxetine in pediatric depression: explanations, lack of acknowledgment, and implications for other treatments
Keywords Antidepressants Fluoxetine Efficacy Pediatric Meta-analysis Biases Guidelines • The efficacy of fluoxetine for pediatric depression has lost clinical significance. • This has not been adequately addressed in guidelines of major medical organizations. • The novelty bias and expectancy effects may explain the loss of estimated efficacy. • Recommending fluoxetine as a first-line treatment is at odds with the evidence.
A Call for Evidence-Based, Fear-Free Practice
In this article I will take a closer look at two statements by leading psychiatrists (Olfson, 2025; Strawn & Walkup, 2025) in response to the criticism about psychiatric drugs raised by “Make America Healthy Again” (MAHA) (The White House, 2025). Without doubt, there are good reasons to be critical of MAHA. For example, as I am writing this (22.
Restoring STAR*D: A Reanalysis of Drug-Switch Therapy After Failed SSRI Treatment Using Patient-Level Data with Fidelity to the Original STAR*D Research Protocol
The authors have declared no competing interest. NCT00021528 Funding for this project was provided by the RIAT Support Center and also partially supported by the National Institute of General Medical Sciences under Award Number P20GM104420. I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Desperate Measures: Ghaemi’s Response to Our Review of Lithium and Suicide Prevention
Nassir Ghaemi, professor of psychiatry at Tufts, recently responded to a systematic review we conducted on the evidence for the common claim that lithium prevents suicide. The content and style of Ghaemi’s article, which is more of a rant than a scientific commentary, suggest he was extremely upset that this cherished belief had been challenged (Ghaemi, 2022). The manner of its publication in the Journal of Psychopharmacology implies he was not alone.
Demedicalizing Depression: An Interview with Milutin Kostić
Milutin Kostić is a practicing Serbian psychiatrist trained in the tradition of biological psychiatry who has become a new figure in the critical psychiatry movement. Affiliated with the Institute of Mental Health in Belgrade, Serbia, he is currently a Fulbright scholar working alongside Lisa Cosgrove in Boston to challenge established norms in psychiatry and psychology. Kostić utilizes his extensive training and traditional research methods to question the fundamental assumptions of his field.
All smoke, no fire
Dear Editor Jauhar and colleagues have launched a ferocious attack on our review. They do not question the conclusion of our review that low serotonin does not cause depression,[1] but continue to claim that ‘changes in serotonin’ occur in depression.
No Clear Evidence of Reduced Brain Serotonin Release Capacity in Patients With Depression
The serotonin hypothesis of depression proposes that diminished serotonergic (5-HT) neurotransmission is causal in the pathophysiology of the disorder. Although the hypothesis is over 50 years old, there is no firm in vivo evidence for diminished 5-HT neurotransmission. We recently demonstrated that the 5-HT receptor agonist positron emission tomography (PET) radioligand [11C]Cimbi-36 is sensitive to increases in extracellular 5-HT induced by an acute d-amphetamine challenge.
Data modelling in search of meaning
Dear Editor Like previous meta-analyses, the FDA individual patient data analysis of antidepressant trials reveals a small average difference between antidepressants and placebo of 1.75 points [95% CI: 1.63 to 1.86] on the HAM-D, a difference likely not clinically important.[1–4] The authors used finite mixture modelling with three normal sub-distributions of participant responses from the data without a pre-registered protocol.
Differences by sexual orientation in treatment outcome and satisfaction with treatment among inpatients of a German psychiatric clinic
Loading metrics Open Access Peer-reviewed Research Article Martin Plöderl , Robert Mestel, Clemens Fartacek Martin Plöderl, Robert Mestel, Clemens Fartacek Published: January 21, 2022 https://doi.org/10.1371/journal.pone.0262928 Figures Abstract A wealth of research suggests that sexual minority individuals experience stigma and lack of sexual minority specific competencies in mental health care, which could lead to less optimal treatment outcome.
Estimates of the minimal important difference to evaluate the clinical significance of antidepressants in the acute treatment of moderate-to-severe depression
Estimates of the minimal important difference to evaluate the clinical significance of antidepressants in the acute treatment of moderate-to-severe depression Abstract The efficacy of antidepressants in the acute treatment of moderate-to-severe depression remains a controversial issue. The minimal important difference (MID) is relevant to judge the clinical significance of treatment effects. In this analysis paper, we discuss estimates of the MID for common depression outcome measures.
Moon and suicide: a true effect or a false-positive finding?
References 1. Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2:e124. Article Google Scholar 2. Forstmeier W, Wagenmakers E-J, Parker TH. Detecting and avoiding likely false-positive findings – a practical guide: avoiding false-positive findings. Biol Rev. 2017;92:1941–68. Article Google Scholar 3. Tajika A, Ogawa Y, Takeshima N, Hayasaka Y, Furukawa TA. Replication and contradiction of highly cited research papers in psychiatry: 10-year follow-up. Br J Psychiatry.
Efficacy of new-generation antidepressants assessed with the Montgomery-Asberg Depression Rating Scale, the gold standard clinician rating scale: A meta-analysis of randomised placebo-controlled trials
Loading metrics Open Access Peer-reviewed Research Article Michael P. Hengartner , Janus C. Jakobsen, Anders Sørensen, Martin Plöderl Michael P. Hengartner, Janus C.
Associations of Suicide Rates With Socioeconomic Status and Social Isolation: Findings From Longitudinal Register and Census Data
Introduction Suicide constitutes a substantial public health problem: In Europe, the local age-adjusted numbers amounted to 12.84 deaths per 100,000 individuals in 2016, according to WHO data (1). This constitutes the second highest suicide rate across all WHO global regions. In order to improve the situation, suicide prevention has been given highest priority on the agenda of the European Comission (2).
Sertraline in primary care: comments on the PANDA trial
The placebo-controlled PANDA trial was negative regarding the effects of sertraline on the primary outcome of depressive symptoms at week 6 (effect size 0·09) and there was only a marginal effect at week 12 (effect size 0·18). 1 Lewis G Duffy L Ades A et al. The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled randomised trial. Lancet Psychiatry.
Suicides Are Increasing – And So Are Antidepressant Prescriptions - Mad In America
Suicide rates decreased steadily from the mid-eighties until the new millennium in the USA and, on average, in Organisation for Economic Cooperation and Development (OECD) countries. In Europe, suicide rates decreased until around 2007 in most countries. Parallel to this drop of suicides, prescriptions of SSRI’s, the new generations of “antidepressants,” gradually increased.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Martin
Contact Martin, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack